Dapagliflozin associated with reduced risk of total heart failure events and cardiovascular death
1. In this prespecified analysis of the DELIVER trial, among 6263 patients, dapagliflozin reduced the risk of total heart failure ...
Tag: DELIVER
Sodium-glucose cotransporter-2 inhibitors are of intermediate or low economic value in the treatment of heart failure with preserved ejection fraction
1. Sodium-glucose cotransporter-2 inhibitors (SGLT2-I) in combination with standard of care were found to increase quality-adjusted life-years at a cost ...
Optimal implementation of sodium-glucose cotransporter-2 inhibitors in US patients with heart failure estimated to cause a significant reduction in worsening heart failure events over 3 years
1. In this decision analytical model study among 4.8 million adults with heart failure in the United States, optimal implementation ...